 Last week, Catalent Inc NYSE: CTLT received an FDA write-up for its syringe filling facility in Belgium, allegedly the culprit behind supply shortage for Novo Nordisk ASs NYSE: NVO obesity drug Wegovy, reported BioProcess International reported. An FDA inspection of the CDMOs filling site in Brussels yielded a Form 483, the publication said, calling it a recent inspection. 